4.8 Article

Reprogramming in vivo produces teratomas and iPS cells with totipotency features

期刊

NATURE
卷 502, 期 7471, 页码 340-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nature12586

关键词

-

资金

  1. CNIO
  2. Spanish Ministry of Economy (MINECO, SAF)
  3. Regional Government of Madrid (ReCaRe)
  4. European Union (RISK-IR)
  5. Botin Foundation
  6. Ramon Areces Foundation
  7. AXA Foundation
  8. MINECO(BFU)
  9. Regional Government of Madrid (Cell-DD)
  10. ProCNIC Foundation

向作者/读者索取更多资源

Reprogramming of adult cells to generate induced pluripotent stem cells (iPS cells) has opened new therapeutic opportunities; however, little is known about the possibility of in vivo reprogramming within tissues. Here we show that transitory induction of the four factors Oct4, Sox2, Klf4 and c-Myc in mice results in teratomas emerging from multiple organs, implying that full reprogramming can occur in vivo. Analyses of the stomach, intestine, pancreas and kidney reveal groups of dedifferentiated cells that express the pluripotency marker NANOG, indicative of in situ reprogramming. By bone marrow transplantation, we demonstrate that haematopoietic cells can also be reprogrammed in vivo. Notably, reprogrammable mice present circulating iPS cells in the blood and, at the transcriptome level, these in vivo generated iPS cells are closer to embryonic stem cells (ES cells) than standard in vitro generated iPS cells. Moreover, in vivo iPS cells efficiently contribute to the trophectoderm lineage, suggesting that they achieve a more plastic or primitive state than ES cells. Finally, intraperitoneal injection of in vivo iPS cells generates embryo-like structures that express embryonic and extraembryonic markers. We conclude that reprogramming in vivo is feasible and confers totipotency features absent in standard iPS or ES cells. These discoveries could be relevant for future applications of reprogramming in regenerative medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据